ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
다우존스 지수
38,686.32
1.51%
Bitcoin
67,570.93
0.13%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 유럽
  5. EU
  6. Cellectis Nom Eo 05 (ALCLS)

  7. Cellectis Nom Eo 05 (ALCLS) 뉴스

ALCLS

Cellectis Nom Eo 05 (ALCLS)

Cellectis Nom Eo 05
일자:
정렬 기준:
 검색 관련기사 보기:EU:ALCLS
일자시간출처헤드라인심볼기업
2024/05/3005:30GlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024EU:ALCLSCellectis Nom Eo 05
2024/05/3005:30GlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024EU:ALCLSCellectis Nom Eo 05
2024/05/3005:30GlobeNewswire Inc.L’ Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2024EU:ALCLSCellectis Nom Eo 05
2024/05/2905:30GlobeNewswire Inc.Cellectis publie ses résultats financiers du premier trimestre 2024EU:ALCLSCellectis Nom Eo 05
2024/05/2905:30GlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024EU:ALCLSCellectis Nom Eo 05
2024/05/2805:30GlobeNewswire Inc.Cellectis publiera ses résultats financiers du premier trimestre 2024 le 28 mai 2024EU:ALCLSCellectis Nom Eo 05
2024/05/2805:30GlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024EU:ALCLSCellectis Nom Eo 05
2024/05/2805:30GlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024EU:ALCLSCellectis Nom Eo 05
2024/05/1705:30GlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
2024/05/1705:30GlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
2024/05/0705:30GlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
2024/05/0705:30GlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
2024/05/0615:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaEU:ALCLSCellectis Nom Eo 05
2024/05/0615:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaEU:ALCLSCellectis Nom Eo 05
2024/05/0615:00GlobeNewswire Inc.Cellectis annonce la réalisation de l’investissement additionnel d’AstraZenecaEU:ALCLSCellectis Nom Eo 05
2024/05/0305:30GlobeNewswire Inc.Cellectis nomme Arthur Stril directeur financier par intérimEU:ALCLSCellectis Nom Eo 05
2024/05/0305:30GlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerEU:ALCLSCellectis Nom Eo 05
2024/05/0305:30GlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerEU:ALCLSCellectis Nom Eo 05
2024/04/3005:46GlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023EU:ALCLSCellectis Nom Eo 05
2024/04/3005:46GlobeNewswire Inc.Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023 EU:ALCLSCellectis Nom Eo 05
2024/04/3005:46GlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023EU:ALCLSCellectis Nom Eo 05
2024/04/2305:30GlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsEU:ALCLSCellectis Nom Eo 05
2024/04/2305:30GlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsEU:ALCLSCellectis Nom Eo 05
2024/04/2305:30GlobeNewswire Inc.Cellectis présente de nouveaux procédés d’éditions par TALEN® permettant une insertion et une correction du génome très efficaces dans les cellules souches progénitrices et hématopoïétiques (CSPHs)EU:ALCLSCellectis Nom Eo 05
2024/04/1105:30GlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsEU:ALCLSCellectis Nom Eo 05
2024/04/1105:30GlobeNewswire Inc.Cellectis publie une nouvelle approche d'édition intronique pour le traitement des maladies métaboliques congénitales par des cellules souches hématopoïétiques modifiéesEU:ALCLSCellectis Nom Eo 05
2024/04/1105:30GlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsEU:ALCLSCellectis Nom Eo 05
2024/04/0905:30GlobeNewswire Inc.Cellectis présentera deux posters sur un nouveau procédé d’édition par TALEN® pour la correction et l’insertion de gènes dans les cellules souches et progénitrices hématopoïétiques (HSPCs) à l’ASGCTEU:ALCLSCellectis Nom Eo 05
2024/04/0905:30GlobeNewswire Inc.Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingEU:ALCLSCellectis Nom Eo 05
2024/04/0905:30GlobeNewswire Inc.Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingEU:ALCLSCellectis Nom Eo 05
 검색 관련기사 보기:EU:ALCLS

최근 히스토리

LSE
C8M
Amundi Eu Mater
LATK
SAITAMAUSDT
Saitama Inu
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유